301080 Acrobiosystems
- 33.84
- +0.33+0.98%
Acrobiosystems News
Baipsis (301080): Regular business revenue increased 19% year-on-year, GMP production sites entered the trial production stage
Bepsyth (301080): Regular business accelerates month-on-month and continues to deepen clinical layout
Pepsis (301080): 2Q profit growth is pressured by steady revenue growth
Baipsis (301080): Regular business maintains high growth, global layout strategy continues to deepen
Baipsis (301080): Regular business maintains high growth, global layout strategy continues to deepen
Baipsis (301080): Overseas routine business maintains high growth and actively lays out clinical business
Baipsis (301080): Regular business growth trends are good, R&D reserves are sufficient
Baipsis (301080): Revenue is in line with market expectations and deepens global layout strategy
Baipsis (301080): Specific disruptions are gradually bottoming out, and overseas growth continues to be high
Baipsis (301080): Global market share continues to increase, deepening clinical layout and undertaking opportunities
Baipsis (301080): Regular business revenue increased 29.5% year-on-year, and the Suzhou production base is about to be put into operation
SDIC Securities released a research report on April 26 stating that the target price for Baipsis (301080.SZ) was given a purchase rating of 43.80 yuan. The main reasons for the rating include: 1) regular business has maintained high growth, and overseas m
Bepsyth (301080) Company Information Update Report: Continued High Growth in Regular Business, High Expenses Affect Short-Term Profits
Dongwu Securities released a research report on April 24 stating that it gave Baipsis (301080.SZ) a buy rating. The main reasons for the rating include: 1) revenue deceleration and increased expenses, and short-term pressure on profits; 2) continuous impr
Baipsis (301080): Short-term profits are under pressure, product development and overseas markets are gradually entering a harvest period
Baipsis (301080): High growth in regular business, impressive overseas revenue growth
Bepsyth (301080) Company Brief Review Report: Valuations are cost-effective and are expected to benefit from overseas biomedical recovery
Baplus Sys (301080): Leading innovative products for recombinant protein reagents continue to be upgraded
Bypsyth (301080) Company Brief Review Report: Overseas Performance Continues to Grow, Business Expansion, Profit Side Is Under Short-Term Pressure
Bypsyth (301080): Regular business grows steadily, profits are under pressure for a short time
Analysis
Price Target
No Data
